

Xpert™ MRSA/SA SSTI

*Detect MRSA & SA Skin and Soft Tissue Infections
In Less Than One Hour*



Xpert™ MRSA/SA SSTI:

The tremendous increase of both hospital acquired and community acquired MRSA in skin and soft tissue infections (SSTIs) requires a change in management of these infections¹. Cepheid's on-demand Xpert MRSA/SA SSTI test detects the presence of *S. aureus* (SA) or methicillin-resistant *S. aureus* (MRSA) in skin and soft tissue infections in less than one hour.

Xpert:
in action

SSTIs are a major health concern

- The most common cause of skin and soft tissue infections is *Staph aureus*; MRSA represents over 50% of these infections in parts of the U.S.²
- Current laboratory methods can take up to 72 hours to determine if a SSTI is SA or MRSA
- Empiric treatment, found to be incorrect in 57% of patients according to one study, is employed due to lack of a rapid identification method³

The only rapid and comprehensive SSTI test available

- Xpert MRSA/SA SSTI is a rapid, on-demand test for detecting MRSA and SA from skin and soft tissue swabs in less than one hour
- Xpert MRSA/SA SSTI is the most comprehensive *Staph aureus* test available:
 - Includes targets for *Staph aureus*, MRSA, and *mecA*
 - Identifies presumptive positive “empty cassette” strains for correct classification as SA sensitive
 - Unparalleled automation with the GeneXpert® System provides reduced hands-on time and improved laboratory efficiency



Important healthcare benefits of rapid detection

- Helps ensure the right therapy sooner for improved patient management
- Enables a targeted antimicrobial therapy approach for better antimicrobial stewardship
- Allows for immediate identification of patient infection for improved isolation and infection control measures

Sensitive and Specific:

Effective management of SSTIs requires the rapid and accurate identification of MRSA/SA infections.

MRSA/SA Performance in Subjects with No Antibiotic Use (within 3 weeks of sample collection) vs. Reference Culture

		Culture			
		MRSA+	SA+/MRSA-	Neg/No Growth	Totals
Xpert	MRSA+	137 ^a	2	6	145
	SA+/MRSA-	3 ^b	79	16	98
	SA-	6	4	188	198
	Total	146	85	210	441

^a 1 of the 137 were mixed infections of MRSA and SA.

^b 2 of the 3 were mixed infections of MRSA and SA.

Summary of results.

	Positive Percent Agreement	Negative Percent Agreement
MRSA	93.8%	97.3%
SA	95.7%	89.5%

Performance characteristics of Xpert™ MRSA/SA SSTI were determined in a multi-site prospective investigation study at three institutions by comparing the Xpert MRSA/SA SSTI test on the GeneXpert® System to enriched culture, the most sensitive culture method.

Comprehensive:

Capable of detecting strains with all SCCmec types found in both healthcare-acquired and community-acquired MRSA.

	Type
Samples	Swabs collected for routine care of SSTIs
SCCmec	I, II, III, IVa, V, VI

The Xpert™ MRSA/SA SSTI advantage: **simplicity**

- Rapid results to improve patient management
- Fully integrated reagent and instrument system for accuracy and reproducibility
- Random access for flexibility and workflow optimization
- Fully automated process reduces hands-on time to just minutes

1. Insert swab into Elution Reagent vial and break at score
2. Vortex and dispense Sample into port S
3. Dispense Reagent 1 into port 1
4. Dispense Reagent 2 into port 2
5. Insert cartridge and start assay

✓ Total hands-on time = 2 minutes

Ordering Information

Xpert™ MRSA/SA SSTI Catalog No. GXMRSA/SA-SSTI-10
(10 cartridges with reagents)

References:

1. *Antimicrob Agents Chemother.* 2007 Feb;51(2):423–8. Epub 2006 Nov 20. Treatment and outcomes of infections by methicillin-resistant *Staphylococcus aureus* at an ambulatory clinic. Szumowski JD, Cohen DE, Kanaya F, Mayer KH.
2. CDC Press release 09/08/2008 entitled “CDC Steps Up Efforts to Fight Drug-Resistant Germ”
3. Moran et al. “Methicillin-Resistant *S. aureus* Infections among Patients in the Emergency Department”, *NEJM* 355:664–674; 2006.

This product is sold under license from bioMérieux under US Patent No. 6,156,507 and corresponding claims of any non-US counterpart(s) thereof.

THE PURCHASE OF THIS PRODUCT ALLOWS THE PURCHASER TO USE IT FOR THE PERFORMANCE OF DIAGNOSTIC SERVICES FOR HUMAN IN VITRO DIAGNOSTICS. NO GENERAL PATENT OR OTHER LICENSE OF ANY KIND OTHER THAN THIS SPECIFIC RIGHT OF USE FROM PURCHASE IS GRANTED HEREBY.

NO OTHER RIGHTS ARE CONVEYED EXPRESSLY, BY IMPLICATION OR BY ESTOPPEL TO ANY OTHER PATENTS. FURTHERMORE, NO RIGHTS FOR RESALE ARE CONFERRED WITH THE PURCHASE OF THIS PRODUCT.

WWW.CEPHEID.COM

CORPORATE HEADQUARTERS

904 CARIBBEAN DRIVE
SUNNYVALE, CA 94089
USA
TOLL FREE: 1.888.336.2743
PHONE: 1.408.541.4191
FAX: 1.408.734.1346

EUROPEAN HEADQUARTERS

VIRA SOLELH
81470 MAURENS-SCOPONT
FRANCE
PHONE: 33.563.82.53.00
FAX: 33.563.82.53.01



0257-01